APO-Bortezomib bortezomib 3.5mg powder for injection vial

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

bortezomib, Quantity: 3.5 mg

Disponible des:

Arrotex Pharmaceuticals Pty Ltd

Designació comuna internacional (DCI):

Bortezomib

formulario farmacéutico:

Injection, powder for

Composición:

Excipient Ingredients: mannitol

Vía de administración:

Subcutaneous, Intravenous

Unidades en paquete:

1

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

Resumen del producto:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Estat d'Autorització:

Licence status A

Data d'autorització:

2015-07-22